CUTRQ Quote, Financials, Valuation and Earnings

Electromed has a net margin of -- compared to Cutera's net margin of 12.11%. Cutera's return on equity of -- beat Electromed's return on equity of 15.91%.

Cutera has a consensus price target of --, signalling upside risk potential of 9116.59%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 50.28%. Given that Cutera has higher upside potential than Electromed, analysts believe Cutera is more attractive than Electromed.

Cutera has a beta of 1.358, which suggesting that the stock is 35.755% more volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

Cutera has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cutera pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Cutera quarterly revenues are --, which are smaller than Electromed quarterly revenues of $16.3M. Cutera's net income of -- is lower than Electromed's net income of $2M. Notably, Cutera's price-to-earnings ratio is -- while Electromed's PE ratio is 32.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cutera is 0.00x versus 3.70x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX has a net margin of -- compared to Cutera's net margin of -16.69%. Cutera's return on equity of -- beat IRIDEX's return on equity of -157.91%.

Cutera has a consensus price target of --, signalling upside risk potential of 9116.59%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 76.99%. Given that Cutera has higher upside potential than IRIDEX, analysts believe Cutera is more attractive than IRIDEX.

Cutera has a beta of 1.358, which suggesting that the stock is 35.755% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.936, suggesting its less volatile than the S&P 500 by 6.383%.

Cutera has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cutera pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

Cutera quarterly revenues are --, which are smaller than IRIDEX quarterly revenues of $11.6M. Cutera's net income of -- is lower than IRIDEX's net income of -$1.9M. Notably, Cutera's price-to-earnings ratio is -- while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cutera is 0.00x versus 0.38x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -- compared to Cutera's net margin of -2.16%. Cutera's return on equity of -- beat Myomo's return on equity of -48.64%.

Cutera has a consensus price target of --, signalling upside risk potential of 9116.59%. On the other hand Myomo has an analysts' consensus of $8.85 which suggests that it could grow by 70.52%. Given that Cutera has higher upside potential than Myomo, analysts believe Cutera is more attractive than Myomo.

Cutera has a beta of 1.358, which suggesting that the stock is 35.755% more volatile than S&P 500. In comparison Myomo has a beta of 1.609, suggesting its more volatile than the S&P 500 by 60.902%.

Cutera has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cutera pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Cutera quarterly revenues are --, which are smaller than Myomo quarterly revenues of $12.1M. Cutera's net income of -- is lower than Myomo's net income of -$260.1K. Notably, Cutera's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cutera is 0.00x versus 6.02x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -- compared to Cutera's net margin of -118.53%. Cutera's return on equity of -- beat Stereotaxis's return on equity of -139.2%.

Cutera has a consensus price target of --, signalling upside risk potential of 9116.59%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 145.9%. Given that Cutera has higher upside potential than Stereotaxis, analysts believe Cutera is more attractive than Stereotaxis.

Cutera has a beta of 1.358, which suggesting that the stock is 35.755% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.546, suggesting its more volatile than the S&P 500 by 54.601%.

Cutera has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cutera pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Cutera quarterly revenues are --, which are smaller than Stereotaxis quarterly revenues of $6.3M. Cutera's net income of -- is lower than Stereotaxis's net income of -$7.5M. Notably, Cutera's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cutera is 0.00x versus 5.79x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.